When will Brigatinib be included in medical insurance?

Brigatinib/BrigatinibThe original drug has been approved by the State Food and Drug Administration for marketing and is sold under the name of Brigatinib tablets. Its trade name is ALUNBRIG/ALUNBRIG. And it has entered the scope of Class B medical insurance through the regulations of the National Medical Insurance Administration, but only patients who meet the indications can be reimbursed, that is, patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).

Brigatinib inhibits the proliferation and in vitro viability of cells expressing the fusion proteinEML4-ALK as well as 17 cyclozotinib-resistant ALK mutants, and its effect extends to cells expressing EGFR deletion, ROS1-L2026M, FLT3-F691L, and FLT3-D835Y. In a mouse EML4-ALK xenograft model, brigatinib dose-dependently inhibited tumor growth, tumor burden, and prolonged survival. The time course and exposure-response studies of brigatinib are unclear.

The original brigatinib drug is marketed in China and included in medical insurance, and has entered the scope of Class B medical insurance. The price of 30 mg * 14 tablets * 2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates). For more drug information and specific prices, please consult Yaode Medical Consultant.